Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors

US Patent 11364300 · Granted Jun 21, 2022

Estimated economic value: $18,819,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as 2025
Bicyclic heteroaryl compounds and uses thereof2025
Ras inhibitors2025
Ras inhibitors2025
Factor VIII zwitterionic polymer conjugates2025
Ras inhibitors2025
C26-linked rapamycin analogs as mTOR inhibitors2025
C26-linked rapamycin analogs as mTOR inhibitors2025
C26-linked rapamycin analogs as mTOR inhibitors2025
Synthesis of antibacterial aminoglycoside analogs2024
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors2024
C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors2024